Lixte Biotechnology Holdings, Inc. and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’S Lead Compound Lb-100 to Treat Small Cell Lung Cancer
January 19, 2021 at 02:35 pm
Lixte Biotechnology Holdings, Inc. announced an agreement on a Phase 1b clinical trial with City of Hope. The trial will assess the combination of Lixte’s first-in-class protein phosphatase inhibitor LB-100 with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC). LB-100 will be given in combination with carboplatin, etoposide and atezolizumab, an FDA approved but marginally effective regimen, in previously untreated ED-SCLC. The dose of LB-100 will be escalated with fixed doses of the 3-drug regimen to reach a recommended Phase 2 dose (RP2D). Patient entry will then be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm its safety and to look for objective evidence of potential therapeutic activity as assessed by objective response rate, duration of overall response, progression-free-survival and overall survival.